CRMD Latest Headlines

CorMedix Reaffirms 2026 Revenue Guidance and Points to a Q1 2027 DefenCath Add-on of $8.32 per Dialysis Session

Market Chameleon (Mon, 2-Nov 7:56 AM)

CorMedix: DefenCath Reimbursement Boost and Growth Opportunities Support Buy Rating, $13 Price Target

at www.tipranks.com (Mon, 2-Nov 9:17 AM)

CorMedix Reports Strong Cash Position, Reaffirms 2026 Revenue Guidance

at www.tipranks.com (Mon, 2-Nov 8:01 AM)

CorMedix Delivers Record Q2 Revenue and Raises 2026 EBITDA Outlook After DefenCath Expansion

Market Chameleon (Thu, 13-Aug 10:37 AM)

CorMedix Posts Robust Q2 Revenue, Ups EBITDA Guidance—DefenCath Drives Growth and Margin Expansion

Market Chameleon (Thu, 13-Aug 8:15 AM)